The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects.
Open accessAbstract
The three major isoforms of human apolipoprotein E (apo-E2, -E3, and -E4) are coded for by three alleles (epsilon 2, epsilon 3, and epsilon 4) which have a common genetic locus. Previously, we demonstrated that E2, E3, and E4 differ in primary structure from one another at two substitution sites, site A (residue 112) and site B (residue 158). At sites A/B, apo-E2, -E3, and -E4 contain cysteine/cysteine, cysteine/arginine, and arginine/arginine, respectively. We demonstrated that the substitution of cysteine for arginine at site B is at least partly responsible for the defective binding of apo-E2 to human fibroblast low density lipoprotein receptors, compared to the normal binding activity of apo-E3 or -E4. Subjects with the genetic disorder type III hyperlipoproteinemia are phenotypically homozygous for apo-E2, but the binding activity of apo-E to the fibroblast receptor differs considerably from one type III individual to another. We therefore undertook a partial comparative sequence analysis of apo-E2 from three type III subjects whose apo-E displayed this heterogeneity. The subject with the poorest binding apo-E2 was genotypically homozygous for an apo-E allele (epsilon 2); cysteine was found at sites A and B. The subject with the most active apo-E2 was genotypically homozygous for an apo-E allele (epsilon 2); cystine was found at site A and at a new site (site C, residue 145). The epsilon 2 allele specifies a protein that has arginine at site B (residue 158); the epsilon 2 allele specifies a protein that has arginine at site C (residue 145). Therefore, the two alleles differ from one another by cysteine/arginine interchanges at two positions, sites B and C. The third subject, whose apo-E2 displayed binding activity intermediate between the activities of the other two, was genotypically heterozygous, having one epsilon 2 allele and one epsilon 2 allele. The intermediate binding activity of apo-E2 from this subject resulted from having a mixture of severely defective apo-E (specified by epsilon 2) and slightly defective apo-E (specified by epsilon 2).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Three variants ofapo E2 have been described.Each ofthese differs from apo E3 by a single amino acid substitution (6, 12- 14).”
From Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. (1987) · cites this paper as [14]
In the citing paper
“The most common has a mutation of 158 Arg --Cys (13), but mutations of 145 Arg -* Cys (14) and 146 Lys --Gln (6) have also been reported in individuals with type III hyperlipoproteinemia.”
From Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. (1987) · cites this paper as [14]
In the citing paper
“Homozygosity and heterozygocity for the apoE variant apoE3[R145C] has also been associated with severe type III HLP [30], [31].”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [30]
In the citing paper
“and the 22-kDa domain of lipid-bound apoE3[R145C] has 48% reduced HSPG binding capacity compared to apoE3-22kDa [30], [32].”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [30]
In the citing paper
“Binding studies showed that lipid-bound apoE3[R145C] has 55% reduced LDL receptor binding capacity compared to apoE3”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [30]
In the citing paper
“Still, these variants not only maintain their ability to predispose to type III HLP, but also do so in a dominant fashion, unlike apoE2 [22], [26], [30], [31], [33], [34], [35].”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [30]
In the citing paper
“In contrast, all apoE3 variants studied here demonstrate stronger LDL receptor binding compared to wild-type apoE2 [28], [30], [34], [35].”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [30]
In the citing paper
“While heterozygosity for three further mutants (apoE2(145 Arg→Cys) (32, 33), apoE2(146 Lys→Gln) (34), or apoE2-Christchurch(136 Arg→Ser) (18, 33)) is associated with type III hyperlipoproteinemia, there are no family studies to ascertain whether these variants also demonstrate a dominant mode of inheritance.”
From Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121–127 (1989) · cites this paper as [32]
In the citing paper
“Prior studies [7][8][9] and Alzheimer Disease Sequencing Project (ADSP) data have shown that R145C is always in phase with ε3 and R150H is always in phase with ε2.”
From Association of African Ancestry–Specific APOE Missense Variant R145C With Risk of Alzheimer Disease (2023) · cites this paper as [8]
Citations
Cites
Weisgraber, K. H., Rall, S. C., & Mahley, R. W. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52510-8 · Cited by 777
Self-citationHuman apolipoprotein E. The complete amino acid sequence
Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34702-1 · Cited by 741
Self-citationWeisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34954-8 · Cited by 673
Self-citationZannis, V. I., & Breslow, J. L. (1981) · Biochemistry · doi:10.1021/bi00507a059 · Cited by 563
Innerarity, T. L., & Mahley, R. W. (1978) · Biochemistry · doi:10.1021/bi00601a013 · Cited by 433
Self-citationSherrill, B. C., Innerarity, T. L., & Mahley, R. W. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85951-3 · Cited by 426
Self-citationPolymorphism of apolipoprotein E
Utermann, G., Vogelberg, K. H., Steinmetz, A., Schoenborn, W., Pruin, N., Jaeschke, M., Hees, M. T. I. W. S.-V., & Canzler, H. (1979) · Clinical Genetics · doi:10.1111/j.1399-0004.1979.tb02027.x · Cited by 408
Lipoprotein binding to canine hepatic membranes. Metabolically distinct apo-E and apo-B,E receptors.
Hui, D. Y., Innerarity, T. L., & Mahley, R. W. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69254-9 · Cited by 383
Self-citationMahley, R. W., Hui, D. Y., Innerarity, T. L., & Weisgraber, K. H. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110365 · Cited by 373
Self-citation(1981) · PubMed · Cited by 341
Cited by
Sorted by citations
Items 301–345 of 345
Genes implicados en la hiperlipemia familiar combinada
López‐Ruiz, A., Martínez-Triguero, M. L., Morillas-Ariño, C., & Mijares, A. H. (2006) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(06)73659-2 · Cited by 1
Apolipoprotein E Polymorphism And It’s Lifestyle Impact
Thahira, A., Kumar, D. T., Dhanya, M. S., Rasitha, C. H., Rajan, A., Pinchulatha, K., Harisree, P. H., Deepthi, S., Aiganesh, I., Jeyapal, V., et al. (2024) · Journal Of Advanced Zoology · doi:10.17762/jaz.v45i1.2925 · Cited by 1
Kondkar, A. A., Azad, T. A., Sultan, T., Khatlani, T., Alshehri, A., Radhakrishnan, R., Lobo, G. P., Alsirhy, E. Y., Almobarak, F. A., Osman, E. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084571 · Cited by 2
Leuven, J. A. G., Hessel, L. W., de Smit, M. H., & Havekes, L. M. (1989) · Springer eBooks · doi:10.1007/978-1-4613-0753-2_52 · Cited by 1
The molecular mechanisms of inherited hypercholesterolemia
März, W., Nauck, M., Fisher, E. A. A., Hoffmann, M. M., & Wieland, H. (2000) · Steinkopff eBooks · doi:10.1007/978-3-642-57724-6_13 · Cited by 1
Frecuencias genotípicas y alélicas de apolipoproteina e (APOE) en una muestra de adultos en Bogotá
Gómez, C. R., Gutiérrez-Castañeda, L. D., Pedraza, O. L., Torres-Tobar, L. A., Acevedo, G. H., Suárez, A., Lozano-Ruiz, A. G., & Camacho, I. (2021) · Revista Repertorio de Medicina y Cirugía · doi:10.31260/repertmedcir.01217372.1008 · Cited by 1
Soto, R. C. (2012) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/2675 · Cited by 1
Lipoprotein Deficiency Syndromes
Sirtori, C. R. (1989) · Recent developments in lipid and lipoprotein research · doi:10.1007/978-3-642-83447-9_11 · Cited by 1
Apolipoprotein e phenotypes and serum lipid levels in apparently healthy male adults in Tokyo
Tsuchiya, S., Yamanouchi, Y., Miyazaki, R., Onuki, M., Yamakawa, K., Kondo, I., Ohnuki, M., & Hamaguchi, H. (1986) · The Japanese Journal of Human Genetics · doi:10.1007/bf01876797 · Cited by 1
Mulder, M. T., Smelt, A. H. M., Zhao, S. P., Frants, R. R., & Havekes, L. M. (1993) · Metabolism · doi:10.1016/0026-0495(93)90082-y · Cited by 1
Gustafson, S., Vessby, B., OSTLUNDLINDGVIST, A., & Ehnholm, C. (1986) · Atherosclerosis · doi:10.1016/0021-9150(86)90060-2 · Cited by 1
Characterisation and Mode of Inheritance of Apolipoprotein E3-Leiden
Havekes, L. M., Utermann, G., de Knijff, P., & Klasen, E. C. (1987) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-1268-0_7 · Cited by 1
Fisher, L. R. (2011) · SUNScholar (Stellenbosch University) · Cited by 1
Receptor Interactions of Human Apolipoprotein E
Weisgraber, K. H., Rall, S. C., Innerarity, T. L., & Mahley, R. W. (1983) · Springer eBooks · doi:10.1007/978-3-642-81817-2_97 · Cited by 1
Self-citationReverse genetics of familial combined hyperlipidaemia.
Worsley, A. P. (1993) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 1
Manotas, M. R. (2009) · Gredos (University of Salamanca) · doi:10.14201/gredos.76537
Havekes, L. M., Smit, M., de Knijff, P., & Klasen, E. C. (1987) · Elsevier eBooks · doi:10.1016/b978-0-08-035588-7.50025-x
Abad‐Rodríguez, J. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.12.002
Classification of primary dyslipoproteinemias
Dargel, R. (1985) · Experimental Pathology · doi:10.1016/s0232-1513(85)80043-8
Polvikoski, T. M. (2004) · Työväentutkimus Vuosikirja
Greenwood, T. (2014) · cIRcle (University of British Columbia) · doi:10.14288/1.0135617
McGladdery, S. H. (2009) · cIRcle (University of British Columbia) · doi:10.14288/1.0089570
APOPROTEIN E3-LEIDEN: A VARIANT OF HUMAN APOLIPOPROTEIN E3
Havekes, L. M., Klasen, E. C., & Utermann, G. (1986)
of a New Structural Variant of Human
Rall, S. C., Weisgraber, K. H., Innerarity, T. L., Bersot, T. P., Mahley, R. W., & Blum, C. B. (1983)
Self-citationNicolosi, R. J., & Zannis, V. I. (2013)
Calvo, M. A. (2017) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/29463
A New Variant of Apolipoprotein E (apo E-Kochi) in a Hyperlipidemic Subject with Broad-beta Band
Suehiro, T., Yoshida, K., TAKAMATSU, K., Kawada, M., Hisatake, K., Yasuoka, N., Kishino, W., Shigetoshi, U. G. A., Mizutani, Y., Yamano, T., et al. (1986) · The Journal of Japan Atherosclerosis Society · doi:10.5551/jat1973.14.3_743
Symposium Genetik der angeborenen Stoffwechselstörungen
Krone, W., Bickel, H., Fredrickson, D. S., Wyngaarden, J. Β., Felig, P., Konigsberg, W., Schweiger, M. R., Desnick, J. R., & SEITELBERGER, F. (1982) · Verhandlungen der Deutschen Gesellschaft für Innere Medizin · doi:10.1007/978-3-642-47093-6_27
Guen, Y. L., Belloy, M. E., Eger, S. J., Chen, A. W., Kennedy, G., Thornton, T. A., Farrer, L. A., Napolioni, V., He, Z., & Greicius, M. D. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3975348
Boehm, M., & Hilaire, C. S. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_4-1
Boehm, M., & Hilaire, C. S. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_4
Triglyceride-Rich Lipoproteins
Le, N., & Brown, W. V. (2000) · doi:10.1007/978-1-4757-9310-9_5
Triglyceride-Rich Lipoproteins
Le, N., & Brown, W. V. (2003) · doi:10.1007/978-1-4615-6484-3_5
Havekes, L. M., Klasen, E. C., & Utermann, G. (1986) · Springer eBooks · doi:10.1007/978-1-4615-9474-1_26
Apolipoprotein Polymorphism and Multifactorial Hyperlipidaemia
Utermann, G. (1988) · Springer eBooks · doi:10.1007/978-94-009-1259-5_7
Apolipoprotein E and Cholesterol Metabolsim
Mahley, R. W., Rall, S. C., Innerarity, T. L., & Weisgraber, K. H. (1983) · Springer eBooks · doi:10.1007/978-3-642-81817-2_90
Self-citationApolipoprotein E Polymorphism And It’s Lifestyle Impact
Thahira, A., Kumar, D. T., Dhanya, M. S., Rasitha, C. H., Rajan, A., Pinchulatha, K., Harisree, H., Deepthi, S., Inbanathan, J., Jeyapal, V., et al. (2024) · Journal Of Advanced Zoology · doi:10.53555/jaz.v45i1.2941
APOE2 Heterozygosity Reduces Hippocampal Soluble Amyloid-β42 Levels in Non-Hyperlipidemic Mice
Valencia‐Olvera, A. C., Balu, D., Moore, A., Shah, M., Ainis, R., Xiang, B., Saleh, Y., Cai, D., LaDu, M. J., & Tai, L. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231210
Genomic variants associated with type 2 diabetes mellitus among Filipinos
la Paz, E. M. C. C., Nevado, J. B., Paz-Pacheco, E. T., Jasul, G., Aman, A. Y. C. L., & Francisco, M. D. G. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312291
Normolipidemic Dysbetalipoproteinemia (ApoE-3 Deficiency)
WAKASUGI, T., SAKAI, Y., YOSHIMURA, A., Sakai, T., Watanabe, A., Tatami, R., Ueda, K., Mabuchi, H., & Takeda, R. (1983) · The Journal of Japan Atherosclerosis Society · doi:10.5551/jat1973.10.6_1031
Lennol, M. P., Sánchez-Domínguez, I., Cuchillo‐Ibáñez, I., Camporesi, E., Brinkmalm, G., Alcolea, D. A., Fortea, J., Lleó, A., Sòria, G., Aguado, F., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21485336
Characterization of Hepatitis C Virus interaction with heparan sulfate proteoglycans
Xu, Y. (2014) · theses.fr (ABES) · doi:10.70675/b8c9dc27z15cfz4921zad5czee757d47d341
Approches biochimique, épidémiologique et clinique du métabolisme intégré de la Lipoprotéine (a)
Blanchard, V. (2020) · theses.fr (ABES) · doi:10.70675/3ce7e0fdzecbaz4b18zaf08z34fb33c163ff
Pedersen, J. C., & Berg, K. (1994) · Developments in cardiovascular medicine · doi:10.1007/978-94-011-1130-0_22
Metadata
- Authors
- Rall, S. C., Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W.
- ORCID
- Mahley, R W
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 1982-08
- Volume
- 79
- Issue
- 15
- Pages
- 4696-4700
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC346743
- OpenAlex
- W2081151510
- Cited by
- 345
- References
- 16
- Citations by year
- 2024: 7 · 2023: 2 · 2022: 5 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 6 · 2014: 4 · 2013: 3 · 2012: 7
- FWCI
- 54.05
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- apolipoprotein E, type III hyperlipoproteinemia, LDL receptor, apolipoprotein E isoforms, site-directed mutagenesis, receptor binding activity, genetic polymorphism
- MeSH terms
- Alleles, Amino Acid Sequence, Apolipoproteins, Apolipoproteins E, Genes, Humans, Hyperlipoproteinemia Type III, Receptors, Cell Surface, Low Density Lipoprotein Receptor-Related Protein-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
